Subscribe to RSS Feed

New Blood Test Could Provide More Precise Prostate Cancer Risk Assessment

NEW YORK, NY--(Marketwired - Mar 25, 2014) - A new prostate cancer blood test, currently in testing, may
 soon facilitate more precise prostate cancer diagnosis. Early findings indicate that gene mutations, similar to those identified in breast cancer screenings, may help experts more accurately predict a man's risk of aggressive prostate cancer. More widespread availability of the prostate cancer genetic screener is anticipated within the next year.

Prostate cancer is currently diagnosed through a combination of assessments, including routine prostate-
specific antigen (PSA) blood tests, a digital rectal exam (DRE), and a prostate biopsy. "While the PSA test is very valuable, it is not a prostate cancer specific test," explains David B. Samadi, MD, Chairman of Urology and Chief of Robotic Surgery at Lenox Hill Hospital. "Elevated PSA levels can indicate an enlarged prostate, prostate inflammation, or prostate cancer."

In vetting this new diagnostic tool, researchers are
exploring how second-generation sequencing technology can be used to determine the frequency of mutations in 22 tumor suppressor genes and how those mutations correlate to prostate cancer risk and disease aggression. In an initial study, 191 men with strong family histories of prostate cancer were tested for the 22 tumor suppressor genes. Among the study participants, researchers identified 14 loss-of-function (LoF) mutations commonly associated with aggressive or advanced-stage prostate cancers.

Understanding how the frequency of mutations may predispose men to familial and/or aggressive prostate cancer may change the course of care. "In-depth assessment of an individual's genetic predispositions opens the door to tailored prostate cancer screening; individualized attention is always our goal," said Dr. Samadi.

Prostate cancer genetic testing could mean a more customized approach to prostate cancer prevention, screening, and treatment. The combination of known risk factors and genetic predispositions would allow men to make adjustments in diet and lifestyle, and give medical professionals the opportunity to screen in a very targeted way.

"My hope is that in the near future men who are diagnosed with prostate cancer can leverage genetic knowledge to make treatment decisions based on their individual disease aggression and recurrence risk," stated Dr. Samadi. "For example, if a man carries these genetic mutations we may preemptively start radiation after robotic prostate surgery to further reduce the risk of recurrence."

The study findings were published on February 20, 2014, in the British Journal of Cancer, 

Back to Press Releases

Bookmark Using:
Facebook Twitter LinkedIn Email Yahoo

Share on Facebook

Call to Make an Appointment With Dr. David Samadi:


Click the contact link to learn how Dr. Samadi can help treat your prostate cancer and give you back your quality of life.

* The benefits of robotic surgery cannot be guaranteed as surgery is both patient and procedure specific. Previous surgical results do not guarantee future outcomes.

Wayne Z., USA

How does one begin to express a felt gratitude that is beyond words? My mind tells me just to write all of the many reasons to thank you - Yes, the operation went exactly as you said it would, and I went home the very next day.

Shaya H.

Dr. Samadi’s special wing in Lennox Hill is like a 5-star hotel. I received VIP accommodation for every need!

S. S., USA

I cannot begin to tell you the reaction that I receive when I tell people that I was operated on just three weeks ago and what a remarkable surgeon you are.. I just want to reiterate how fabulous you staff is and how deeply indebted I am to you.

Rita D., USA

It was Dr. Samadi himself wanting to speak with both of us to find out exactly what we needed and how he could help us. Dr. Samadi was a true hero in this story. I love him for what he did and would recommend him to anyone who has been diagnosed with prostate cancer.